Posted: August 25, 2020

Applications due February 24, 2021

A research opportunity is currently available in the Office of Tissues and Advanced Therapies (OTAT), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

The goal of this project is to perform research and receive training on cell engineering with an emphasis on genome editing in human stem cells. Under the guidance of a mentor, the participant will be involved in research projects aimed to evaluate safety and efficacy of novel genome editing technologies for gene therapy, as well as to develop new therapeutic approaches. By precise genome editing, the projects also aim to understand cellular and molecular mechanisms in development and diseases, such as in the immune and hematopoietic systems.

The participant will receive mentoring on project design and execution, as well as training in specific techniques used in genome editing, stem cell maintenance and differentiation. Opportunities will also be provided to the participant to present and discuss research projects within the agency and in national research conferences.

See full solicitation here